Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

Semaglutide.

Research draft

Semaglutide is a GLP-1 receptor agonist used in prescription diabetes and weight-management products.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Semaglutide is a GLP-1 receptor agonist used in prescription diabetes and weight-management products.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It affects glucose-dependent insulin secretion, appetite and gastric emptying.

Human research

Large randomised programmes support specific diabetes, weight-management and other labelled outcomes; benefits depend on population and product.

Preclinical & other research

Mechanistic research explains incretin activity, but clinical trials provide the principal outcome evidence.

Safety & unknowns

Gastrointestinal effects are common. Pancreatic, gallbladder, dehydration and product-specific contraindication warnings require label review.

Regulatory status

Approved oral and injectable products have different labels; approval does not extend to every research or compounded preparation.

Reported use & evidence

Research profile draft

The supplied Semaglutide profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds